Dyslipidemia

The association between genetic liability to smoking and ASCVD was independent from the effects of smoking on traditional cardiovascular risk factors.

A lipidologist from Connecticut describes his experience during the COVID-19 pandemic and explains why he sees getting the vaccine as his "biggest contribution" to healthcare during the pandemic.

Patients who continue RAS therapy had a lower risk of kidney replacement therapy.

This article features the top 6 stories in Practical Cardiology's coverage of lipid management in 2020.

Practical Cardiology Advisory Board Member Brett Nowlan, MD, offers his perspective on the most important advances and topics in the field of lipidology from 2020.

The US FDA has declined to approve inclisiran ahead of its PDUFA date of December 23, instead issuing a CRL citing unresolved facility inspection issues.

Novartis indicates they will address manufacturing issues cited by the FDA.

Learn more about the importance of educating patients on the differences between store-bought fish oil supplements and therapies derived from omega-3 such as icosapent ethyl (Vascepa).

Despite these findings, there is still uncertainty as to whether mitigating symptoms of depression can lower cardiovascular risk.

There is concern over whether or not patients are adhering to their treatment during the pandemic.

Dr. Gerald Shulman discusses how diabetes can eventually be reversed.

By addressing insulin resistance, researchers believe they can reduce the comorbidities associated with type 2 diabetes.

Dr. Giorgino discusses how combining SGLT2 Inhibitors and GLP-1RA could be combined for treating type 2 diabetes.

Diabetic patients are more susceptible to severe COVID-19 outcomes.

Dr. Kausik Ray presents new data on inclisiran and bempedoic acid as cholesterol lowering medications.

New research from the Mayo Clinic is outlining the successes and pitfalls of efforts to improve statin adherence in a comparison of data from the OptumLab Data Warehouse from 2007-2016.

2020 was the year when regulators, clinicians, and patients had no choice but to embrace the concept of wearable monitoring devices. But it’s been a long time coming for the technology class.

Dr. Paul D. Thompson tackles the topic of whether use of fenofibrate helps or harms kidney function.

More studies are planned testing the impact of finerenone.

Finerenone could be another option to SGLT2 inhibitors for this patient population.

Researchers present new data from the SUSTAIN 6 and PIONEER 6 trials during the virtual AHA 2020 conference.

The rates of ALT normalization maintained in both arms of the 96 week study.

The lipid profile changes were not significant after 6 months, while the changes in the lipid profile are due to other factors and not the drugs.

Ongoing debates question whether or not lipid lowering in elderly patients offers similar clinical benefit as in younger patients.

In data from several studies presented at AHA 2020, investigators tout bempedoic acid in patients with atherosclerotic cardiovascular disease and/or heterozygous familial hypercholesterolemia.